At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 167 enrolled
Drug / intervention
LY2189265 and Lifestyle Measures +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions
In Brief
A Phase 2 clinical trial evaluating LY2189265 and Lifestyle Measures and Placebo solution and Lifestyle Measures for Diabetes Mellitus, Type 2. Completed, enrolled 167 participants across 46 sites in 9 countries.
Detailed Summary
This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCroatia, Denmark, India, Mexico, Poland, Puerto Rico, Russia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartDec 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedNov 14, 2008
Enrollment StartDec 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.6 years ago
Interventions
LY2189265 and Lifestyle Measuresdrug
Subcutaneous injection once-weekly for up to 12 weeks
Placebo solution and Lifestyle Measuresdrug
Subcutaneous injection once-weekly for up to 12 weeks